Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection

Janssen (J&J Innovative Medicine)

Status

Conditions: HIV

Treatments: Drug: Rilpivirine Long Acting (RPV LA)

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03847376

TMC278LAHTX2001 (Other Identifier)

CR108331

Details and patient eligibility

About

The main purpose of this pre-approval access program (PAAP) is to provide rilpivirine Long Acting (RPV LA) injectable suspension for the treatment of human immunodeficiency virus (HIV)-1 infection as single patient request to individuals who have no available treatment alternatives and/or limited treatment options (for example, who are unable to participate in the Phase III clinical studies or do not qualify). RPV LA can only be provided if participants are also eligible for cabotegravir Long Acting injections.

Sex

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria